Clinical Trials Logo

Filter by:
NCT ID: NCT04532892 Completed - Burn Out Clinical Trials

A Specialized Nutraceutical for Pre-burnout

WELBI
Start date: March 3, 2020
Phase: N/A
Study type: Interventional

High demands, professional overload and emotional stress are well known negative influences on mental health. Chronic stress-related occupational diseases, especially Burnout, are becoming an important issue. Burnout can be defined as a negative affective state consisting of emotional exhaustion, cognitive weariness and physical fatigue, which is caused by chronic psychosocial stress. Currently, there is no standard treatment for Burnout but different forms of psychological interventions are usually attempted. Also the administration of anxiolytics, antidepressants and sedatives only targets symptoms with a risk of addiction. Recently, adaptogen plants have shown promising effects (e.g. Siberian Ginseng, Panax Ginseng, Rhodiola rosea and Ashwagandha) by increasing the body's ability to resist stress and exert a balancing effect on various systems of the body. This study is focused on the effect of a specialized nutraceutical, containing adaptogen plants (Ashwagandha, Rhodiole rosea, Ginseng) as well as Vitamins and minerals (e.g. Vitamin C) needed for a normal hypothalamus-pituitary-adrenal (HPA) axis regulation in subjects suffering of early Burnout symptoms (pré-Burnout).

NCT ID: NCT04532320 Completed - Clinical trials for Brief Resolved Unexplained Events (BRUE)

Incidence of BRUE Among the Hospitalized Infants: Towards a Change in Medical Practices?

Start date: November 1, 2019
Phase:
Study type: Observational

The malaise of the infant represents a polymorphic pathology in its clinical presentation. Due to the young age of the patients concerned and the parental anxiety generated, hospital management is necessary, for clinical and paraclinical evaluation and monitoring. The practice of complementary examinations is guided by personal and family history, and the precise description of the discomfort as well as clinical examination of the child and assessment of his vital parameters. However, in view of the particular terrain represented by infants under one year of age, a number of tests are carried out systematically, and therefore empirically, because they are not guided by the clinic. These various tests can be invasive, anxiety-provoking for parents and generate a significant additional cost during hospital management. An evaluation of the indication and interest of these tests is necessary in order to propose a homogeneous clinical and paraclinical management of the discomfort of the infant, in particular of discomforts of type BRUE (Brief Resolved Unexplained Events), as described in the 2016 American Academy of Pediatrics (AAP) recommendations.

NCT ID: NCT04532151 Completed - Systemic Sclerosis Clinical Trials

Optical Coherence Tomography Imaging in Systemic Sclerosis

OCTISS
Start date: February 2, 2021
Phase: N/A
Study type: Interventional

Systemic sclerosis (SSc) is an autoimmune disorder characterized by early vascular endothelial involvement. SSc is a rare and devastating multi-visceral disease when fibrotic lesions extend to the skin and other tissues (heart, lungs, kidneys). The severity of skin involvement in SSc is correlated with functional prognosis and survival. To date, there is no validated tool for a reliable quantitative assessment of skin fibrosis. Optical coherence tomography (OCT) is an innovative non-invasive skin imaging technique that allows micrometric analysis of the superficial layers of the skin. Previous study showed that OCT could detect the loss of the dermal-epidermal junction in an objective and non-invasive way, which is correlated with severity of skin fibrosis. The aim of OCTISS study is to evaluate the skin involvement of patients with early SSc using OCT imaging. This will be early diagnosis of fibrosis lesions and help identify patients at an early stage.

NCT ID: NCT04530682 Completed - Clinical trials for Chronic Inflammatory Rheumatism

COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs

COVIDRIC-2
Start date: March 5, 2021
Phase:
Study type: Observational

Accurate knowledge of the humoral immune responses induced by SARS-CoV-2 in patients undergoing immunosuppressive therapy is essential to guide recommendations for infected patients and for vaccination policy for uninfected immunosuppressed patients.

NCT ID: NCT04530344 Completed - Vitiligo Clinical Trials

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

Start date: September 24, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who have completed either Study NCT04052425 or NCT04057573 (parent studies) in which the participants will have been using ruxolitinib cream BID for the previous 28 to 52 weeks depending on their initial randomization in the parent study.

NCT ID: NCT04530292 Completed - Clinical trials for Diabetes Mellitus, Type 1

Home Intervention and Social Precariousness in Childhood Diabetes

PRECADIAB
Start date: September 28, 2020
Phase: N/A
Study type: Interventional

A pilot study of children whose families are in a precarious situation, who will benefit from a targeted at-home intervention by a pediatric nurse. Visits will be organized during the first, fourth and sixth months after the discovery of diabetes. The HbA1C measured 12 months after the diabetes diagnosis will be compared to the HbA1C obtained in an historical cohort that did not receive at-home therapeutic education.

NCT ID: NCT04530175 Completed - Clinical trials for End Stage Renal Disease

Modeling of Regional Citrate Anticoagulation With a Dialysate Containing Calcium in Intermittent Hemodialysis (MARC)

MARC
Start date: February 2, 2021
Phase:
Study type: Observational

The primary purpose of this study is to validate a mathematical modeling of treatment by intermittent hemodialysis using regional citrate anticoagulation with a dialysate containing calcium

NCT ID: NCT04530045 Completed - Sepsis Clinical Trials

Target Attainment of TDM-guided Infusion of Piperacillin/Tazobactam and Cefepim in Critically Ill Patients

DOSATB
Start date: May 2, 2018
Phase:
Study type: Observational

Although alternative dosing strategies can improve antimicrobial exposure in critically ill patients, the high PK variability in this population means that some may still receive sub-optimal antibiotic exposure leading to unfavourable clinical outcomes. Therapeutic drug management (TDM) guided dosing is the only safe and effective way to ensure that all critically ill patients achieve therapeutic antimicrobial exposures and to minimise the likelihood of toxicity. For experts, TDM should be a standard of care, in particular for β-lactams. Nevertheless, because of the assay method for β-lactams and the need for bioanalytical experts, delays in obtaining results frequently occurred. These barriers, combined with difficulties in the interpretation of TDM results, need to be addressed in order to increase its routine utilization. Consequently, study aiming at identify which subgroup of patients or infection are more likely to benefit from TDM are urgently warranted This prospective observational study aimed at evaluating target attainment of piperacillin/tazobactam (PIP/TAZ) and cefepim (CEF) with the use of a Therapeutic Drug Monitoring (TDM) in critically patients during the routine care

NCT ID: NCT04529395 Completed - Clinical trials for Intensive Care Unit Delirium

Impact of Aromatherapy on the Delirium of Patients in Intensive Care Unit

AROMADELI
Start date: September 18, 2020
Phase: N/A
Study type: Interventional

The primary objective of this monocenter randomized controlled trial is to assess the efficacy of aromatherapy to prevent delirium in patients hospitalized in an intensive care unit.

NCT ID: NCT04528043 Completed - Critically Ill Clinical Trials

Infections and Colonization With the Third Group of Enterobacteriaceae in the Intensive Care Unit

EB3REA
Start date: April 1, 2017
Phase:
Study type: Observational

There is a lack of data whether colonization and infection with Enterobacteriaceae of the third group (EB3) affect the outcomes for ICU patients. This study evaluated the effects of EB3 colonization and infection on ICU mortality, ICU length of stay (LOS) and broad-spectrum antibiotic exposure. We focused on the sub type Enterobacter regarding its a priori higher risk of resistance.